Cerebral blood flow and cognitive function in patients with metabolic syndrome: effect of antihypertensive therapy.
The aim of the study was to estimate regional cerebral blood flow (rCBF) and cognitive function in patients with metabolic syndrome (MetS) before and after antihypertensive combination therapy. The study included 24 patients with MetS (average age 52.4±1.6 years). All patients underwent brain single-photon emission computed tomography with technetium-99m hexamethylpropyleneamine oxime and comprehensive neuropsychological testing before and after 6-month antihypertensive combination therapy. All patients with MetS showed lower rCBF values in all regions of the brain compared with the control group. Their parameters of attention, immediate visual memory, and mentation were lower by 25%, 22%, and 13% compared with the control group, respectively. Six-month antihypertensive combination therapy increased cerebral perfusion and improved attention, mentation, and visual memory in MetS patients.
Federal State Budgetary Scientific Institution Research Institute for Cardiology, Tomsk, Russia.
Irina
I
Efimova
Natalya
N
Efimova
Yuri
Y
Lishmanov
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging / Q000503:physiopathology*; D002560:Cerebrovascular Circulation / Q000187:drug effects* / Q000502:physiology; D003071:Cognition / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D008875:Middle Aged; D009483:Neuropsychological Tests; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon
D000959:Antihypertensive Agents; D019690:Technetium Tc 99m Exametazime